MX2020004652A - Tratamiento del síntoma más molesto (smm) asociado a la migraña usando anticuerpos anti-cgrp. - Google Patents

Tratamiento del síntoma más molesto (smm) asociado a la migraña usando anticuerpos anti-cgrp.

Info

Publication number
MX2020004652A
MX2020004652A MX2020004652A MX2020004652A MX2020004652A MX 2020004652 A MX2020004652 A MX 2020004652A MX 2020004652 A MX2020004652 A MX 2020004652A MX 2020004652 A MX2020004652 A MX 2020004652A MX 2020004652 A MX2020004652 A MX 2020004652A
Authority
MX
Mexico
Prior art keywords
migraine
mbs
treatment
cgrp antibodies
bothersome symptom
Prior art date
Application number
MX2020004652A
Other languages
English (en)
Inventor
Jeffrey T L Smith
Roger K Cady
Joseph Hirman
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2020004652A publication Critical patent/MX2020004652A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan métodos para el tratamiento del síntoma más molesto (SMM) asociado a la migraña. Los métodos a modo de ejemplo proporcionan una mejoría en el SMM asociado a la migraña en 1 mes desde la administración de anticuerpos anti-CGRP de la invención. También se proporcionan métodos para la mejoría de la impresión de cambio del paciente (IGCP) asociada a la migraña. Los métodos a modo de ejemplo comprenden la administración de un anticuerpo antagonista anti-CGRP a un paciente que lo necesite.
MX2020004652A 2020-04-06 2020-07-13 Tratamiento del síntoma más molesto (smm) asociado a la migraña usando anticuerpos anti-cgrp. MX2020004652A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063005950P 2020-04-06 2020-04-06

Publications (1)

Publication Number Publication Date
MX2020004652A true MX2020004652A (es) 2021-10-07

Family

ID=70457082

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004652A MX2020004652A (es) 2020-04-06 2020-07-13 Tratamiento del síntoma más molesto (smm) asociado a la migraña usando anticuerpos anti-cgrp.
MX2020008262A MX2020008262A (es) 2020-04-06 2020-08-05 Tratamiento del síntoma más molesto (smm) asociado a la migraña usando anticuerpos anti-cgrp.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020008262A MX2020008262A (es) 2020-04-06 2020-08-05 Tratamiento del síntoma más molesto (smm) asociado a la migraña usando anticuerpos anti-cgrp.

Country Status (9)

Country Link
US (2) US20210309725A1 (es)
JP (1) JP2023531120A (es)
KR (1) KR20210124867A (es)
AU (1) AU2020202454A1 (es)
BR (1) BR102020007149A8 (es)
CA (1) CA3077973A1 (es)
MX (2) MX2020004652A (es)
SG (1) SG10202003296VA (es)
WO (1) WO2021205216A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190071490A1 (en) * 2017-03-02 2019-03-07 Beth Israel Deaconess Medical Center, Inc. Preventing Post-Ictal Headaches

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1996004925A1 (en) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO2008144763A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
HUE055505T2 (hu) 2011-05-20 2021-11-29 H Lundbeck As Anti-CGRP készítmények és alkalmazásuk
AU2012258976B8 (en) 2011-05-20 2017-07-20 H. Lundbeck A/S Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
DK2709663T3 (da) 2011-05-20 2019-05-20 Alderbio Holdings Llc Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
JP6502337B2 (ja) 2013-07-03 2019-04-17 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整
US9896502B2 (en) * 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2021008267A (es) * 2019-01-08 2021-08-05 H Lundbeck As Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp.

Also Published As

Publication number Publication date
BR102020007149A2 (pt) 2021-12-07
US20210309725A1 (en) 2021-10-07
JP2023531120A (ja) 2023-07-21
BR102020007149A8 (pt) 2023-09-26
WO2021205216A1 (en) 2021-10-14
MX2020008262A (es) 2021-10-07
SG10202003296VA (en) 2021-11-29
CA3077973A1 (en) 2021-10-06
KR20210124867A (ko) 2021-10-15
AU2020202454A1 (en) 2021-10-21
US20240101653A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
SA520420801B1 (ar) أil جسام مضادة لـ -11
MXPA05012718A (es) Anticuerpos humanizados que reconocen el peptido beta amiloide.
MX2020010144A (es) Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38).
CR20210373A (es) Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
TW200636066A (en) Humanized antibodies that recognize beta amyloid peptide
NZ746784A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
MX2022004678A (es) Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
PH12021550764A1 (en) Trem2 stabilizing antibodies
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
EA202190378A1 (ru) Антитела против ifnar1 для лечения аутоиммунных заболеваний
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
MX2021013427A (es) Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
MX2021002301A (es) Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
MX2022003820A (es) Metodos de tratamiento para modificar la hermodinamica.
MX2020008262A (es) Tratamiento del síntoma más molesto (smm) asociado a la migraña usando anticuerpos anti-cgrp.
MX2020007429A (es) Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2022011455A (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso.